Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
about
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerFunction of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostatesTMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)Recurrent gene fusions in prostate cancer: their clinical implications and uses.Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis.The oncogene ERG: a key factor in prostate cancer.Current biomarkers for diagnosing of prostate cancer.Biomarkers in localized prostate cancer.Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect.Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.Novel insights into chromosomal conformations in cancer.Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
P2860
Q26784517-226A71F4-9D44-491D-9FE8-CB5156988B02Q34130249-F4AE25D3-73B9-44C6-B5D5-455789AEC76EQ34536729-8397BDA8-F015-4393-A462-99EE9410BB06Q35751842-DE152DEB-1F57-495A-B6E9-86C52E2DDAC7Q36067872-B4A93A3E-9369-48E2-B108-73674AFEF02DQ36772249-3150A71C-91C8-4568-9CD6-958D5754BBA9Q37155070-F200C71C-D663-4E8C-98E9-D844101BF5EAQ38102618-8FFCF914-4A87-4770-BC63-251A10027DE2Q38154209-F9FA6265-8DF4-4C70-A673-3E0EC7656EEEQ38444138-EB49AAA4-CA24-43F4-A25C-860216285FBFQ38584370-4DFBCA43-EC76-4E3E-967D-D962BFFEE943Q38697114-F44D34F3-18A2-48ED-A4B3-173D54A2FFB9Q38703676-AFB47DC6-4A5B-4DC6-BEB2-6F89437728C7Q41609967-7B6F6249-529A-47F9-AF3E-EB57AB14CD16Q42659330-DC075F5F-60DE-4BFE-B19F-DF0F43775734Q47098649-3019A76D-81B3-4E01-A080-96D24C2F98D8Q48858773-84251756-9795-440D-9F53-4EF63CCF50B6
P2860
Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Rational basis for the combina ...... for prostate cancer diagnosis.
@en
Rational basis for the combina ...... for prostate cancer diagnosis.
@nl
type
label
Rational basis for the combina ...... for prostate cancer diagnosis.
@en
Rational basis for the combina ...... for prostate cancer diagnosis.
@nl
prefLabel
Rational basis for the combina ...... for prostate cancer diagnosis.
@en
Rational basis for the combina ...... for prostate cancer diagnosis.
@nl
P2093
P2860
P356
P1433
P1476
Rational basis for the combina ...... for prostate cancer diagnosis.
@en
P2093
Daphne Hessels
Frank Smit
Grégoire Robert
Jack A Schalken
Peter F Mulders
Ruben Cremers
Sander Jannink
Tilly Aalders
P2860
P304
P356
10.1002/PROS.22546
P577
2012-06-05T00:00:00Z